Cargando…
A simple, feasible, efficient and safe treatment strategy of sofosbuvir/velpatasvir for chronic HCV/HIV-1 coinfected patients regardless of HCV genotypes: a multicenter, open-label study in China
BACKGROUND: The direct-acting antiviral agents (DAAs) have revolutionized the treatment of Hepatitis C Virus (HCV) infection. However, a simple and feasible treatment strategy with high efficacy and safety for HCV in patients coinfected with Human Immunodeficiency Virus (HIV) remains an unmet medica...
Autores principales: | Lin, Weiyin, Wang, Xicheng, Zhang, Jianbo, Wen, Chunyan, Kang, Wen, Mao, Lin, Yang, Jie, Dou, Yanyun, Shi, Liying, Dang, Bianli, Lan, Yun, Li, Hong, Li, Yonghong, Chen, Xiejie, He, Haolan, Xu, Min, He, Yaozu, Hu, Fengyu, Lu, Ruichao, Cai, Weiping, Li, Linghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398601/ https://www.ncbi.nlm.nih.gov/pubmed/37547041 http://dx.doi.org/10.1016/j.lanwpc.2023.100749 |
Ejemplares similares
-
Persistently low CD4 cell counts are associated with hepatic events in HCV/HIV coinfected patients: data from the national free antiretroviral treatment program of China
por: Lin, Weiyin, et al.
Publicado: (2022) -
Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020) -
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019) -
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors
por: Chen, Ruoyang, et al.
Publicado: (2021) -
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China
por: Zhang, Hedong, et al.
Publicado: (2022)